Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .
Duloxetine in military posttraumatic stress disorder.
The objective of this prospect i ve study was to assess the efficacy and tolerability of duloxetine in the treatment of in military veterans with posttraumatic stress disorder (PTSD).Twenty subjects were enrolled in this 12-week , open-label trial . Diagnosis and symptom severity were assessed with the Clinician Administered PTSD Scale ( CAPS ) . Depressive symptoms were assessed the Hamilton Depression Rating Scale . All subjects had a CAPS score of at least 60 at baseline . Subjects with lifetime history of psychotic disorders or bipolar illness were excluded . Fifteen participants completed 12 weeks of treatment , five dropped-out from the trial , 3 due to side effects . For patients who discontinued , missing values were estimated using " the last observation carried forward " method . Significant improvements were seen on : CAPS total and all subscales , depression and sleep measures . Most of the improvement was observed by week 2 of treatment . Nine participants ( 45 % ) were classified as responders , defined by 20 % or greater improvement on CAPS total score . The mean daily dose of duloxetine was 81 mg . The most common side effects were constipation ( 20 % ) diarrhea ( 25 % ) and nausea ( 20 % ) . Two subjects developed tachycardia , one withdrew from the trial due to this problem . Duloxetine had a fast onset of action and was effective in about half of the subjects , it was well tolerated in most subjects . These preliminary results in a difficult to treat population warrant the conduction of a double blind , placebo-controlled study of duloxetine in PTSD
Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .